Expert Interview
Second View: Looking at the current treatment landscape and the potential of fenebrutinib, a BTK inhibitor being developed by Roche for the treatment of relapsing multiple sclerosis (RMS)
Ticker(s): RHHBYInstitution: Neurological Consultants
- General neurologist who sees 100 patients with Parkinson's Disease
- Works in a suburban multi specialty group
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
